Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Preliminary phase I data on fully human anti-PNAG mAb F-598 disclosed

Sep. 22, 2010

SCH-527123 is safe and efficacious in phase II trial in COPD

Sep. 21, 2010

NFL-10808 silences presynaptic serotonin 5-HT1A receptors and has antidepressant effects in vivo

Sep. 21, 2010

Scientists reveal predictors of adverse events associated with losartan therapy for heart failure

Sep. 21, 2010

Almirall identifies new naphthyridine N-oxide as anti-inflammatory agent

Sep. 21, 2010

Ramucirumab is tolerated in patients with advanced HCC in ongoing phase II trial

Sep. 21, 2010

VX-770 shows promise in patients with cystic fibrosis

Sep. 20, 2010

Polymorphic variants in HTR2A gene may predict extent of musculoskeletal pain

Sep. 20, 2010

Aviptadil does not improve pulmonary vascular resistance in phase II trial in PAH

Sep. 20, 2010

Researchers describe new mPTP inhibitors

Sep. 20, 2010

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...